Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2022
Second quarter (April-June 2022) · Operating profit/loss totaled SEK -3,641,800 (-1,818,751). · Loss for the period totaled SEK -3,667,200 (-1,818,888). · Cash flow from operating activities totaled SEK -3,877,975 (3,486,666). · Earnings per share before dilution totaled SEK -0.19 (-0.15) Earnings per share after dilution amounted to SEK -0.19 (-0.15). Period (January-June 2022) · Operating profit/loss totaled SEK -8,382,851 (-4,223,302). · Loss for the period totaled SEK -8,421,815 (-4,224,377). · Cash flow from operating activities totaled SEK -9,211,200 (